Search Results
Showing 10 of 83 results
“This ‘invisible pandemic’ is one of the biggest global health challenges”
Dr Riad Dirani specializes in researching the clinical, economic and human impact of non-communicable diseases (NCDs), such as heart disease, stroke, cancer, asthma and diabetes. Riad outlines how his work is helping tackle an “invisible epidemic” and how his Dad’s unexpected experience with diabetes led him to a career in the pharma industry.
Saving Billions While Fueling Economies: Teva’s First-Ever Global Economic Impact Report
Every day, Teva develops, manufactures and supplies quality, critical medicines. Now, Teva’s first-ever Global Economic Impact Report sheds light on how our work impacts economies around the world....
Social Impact at Teva—2018 Progress and More: A Conversation with Amalia Adler-Waxman
Read the latest and past featured stories from Teva Pharmaceuticals, and discover the newest developments of the health section.
A year of impact across the US
Read the latest and past featured stories from Teva Pharmaceuticals, and discover the newest developments of the health section.
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the...
Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Associatio
Findings evaluate safety, quality of life and patient-centered outcome measures up to 145 weeks TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva...
Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy
January 12, 2021 /3BL Media/ - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced long-term environmental sustainability commitments and targets to provide direction and drive...
Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY® (fre
Open-label extension of the FOCUS Phase IIIb study examined changes in quality of life, health status, depressive symptoms and work productivity over 12 weeks Pooled Phase 3 results examined change...
Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report, demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content.
Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injectio
AJOVY data highlight efficacy and safety in difficult-to-treat migraine GALA open-label extension study evaluates 7-year efficacy and safety results of COPAXONE Teva Pharmaceutical Industries Ltd....
